市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | ProKidney Corp. | 看跌 | 看跌 |
AIStockmoo 评分
-1.6
| 分析师共识 | -2.0 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -2.5 |
| 平均 | -1.63 |
|
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 27.44% |
| 机构持股比例 | 43.37% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Suvretta Capital Management, Llc | 30 Sep 2024 | 12,341,266 |
| Bleichroeder Lp | 30 Sep 2024 | 1,845,000 |
| Brown University | 30 Sep 2024 | 1,000,000 |
| Bank Of New York Mellon Corp | 30 Sep 2024 | 190,495 |
| Amundi | 30 Sep 2024 | 155,953 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合